import { EducationalContent } from '../../types';

export const pericardialDisease: EducationalContent = {
  id: 'pericardialdisease',
  type: 'concept',
  name: 'Pericardial Disease',
  nameEs: 'Enfermedad Pericardica',
  levels: {
    1: {
      level: 1,
      summary: 'Pericardial disease refers to conditions affecting the pericardium, the protective sac surrounding the heart, including inflammation (pericarditis), fluid accumulation (effusion), and compression of the heart (tamponade).',
      explanation: 'The heart sits inside a thin, double-layered sac called the pericardium. This sac normally contains a small amount of fluid (about 15-50 mL) that acts as a lubricant, allowing the heart to move smoothly as it beats. Pericardial disease occurs when something goes wrong with this sac. Pericarditis is when the pericardium becomes inflamed, causing sharp chest pain that often worsens with breathing or lying flat and improves when sitting up and leaning forward. The most common cause is a viral infection. Pericardial effusion occurs when too much fluid builds up inside the pericardial sac. If fluid accumulates slowly, the pericardium can stretch to accommodate it. However, if fluid builds up rapidly or becomes very large, it can compress the heart and prevent it from filling with blood properly. This dangerous condition is called cardiac tamponade and is a medical emergency. The heart cannot pump enough blood when it is being squeezed by the fluid, leading to low blood pressure, shortness of breath, and potentially death if not treated quickly. Treatment of tamponade requires drainage of the fluid with a needle (pericardiocentesis). Constrictive pericarditis is a chronic condition where the pericardium becomes thickened and stiff, like a rigid shell around the heart, restricting normal heart filling.',
      keyTerms: [
        { term: 'Pericardium', definition: 'The thin, double-layered sac that surrounds and protects the heart' },
        { term: 'Pericarditis', definition: 'Inflammation of the pericardium, typically causing chest pain that changes with position' },
        { term: 'Pericardial effusion', definition: 'An abnormal accumulation of fluid in the pericardial sac around the heart' },
        { term: 'Cardiac tamponade', definition: 'A life-threatening condition where fluid around the heart compresses it and prevents it from filling properly' },
        { term: 'Pericardiocentesis', definition: 'A procedure using a needle to drain fluid from around the heart' }
      ],
      clinicalNotes: 'The classic presentation of acute pericarditis is sharp, pleuritic chest pain that improves with sitting up and leaning forward. This positional component is a key feature that helps distinguish pericarditis from myocardial infarction. Patients with suspected cardiac tamponade need emergency evaluation and possible emergent drainage.'
    },
    2: {
      level: 2,
      summary: 'Pericardial diseases include acute pericarditis (viral, idiopathic, autoimmune, uremic), pericardial effusion with risk of tamponade, and constrictive pericarditis, each with distinct diagnostic findings and treatment approaches.',
      explanation: 'Acute pericarditis is diagnosed when at least 2 of 4 criteria are present: (1) typical pericarditic chest pain (sharp, pleuritic, positional), (2) pericardial friction rub on auscultation (a scratchy, high-pitched sound), (3) new widespread ST-segment elevation or PR depression on ECG, and (4) new or worsening pericardial effusion on echocardiography. The most common cause is idiopathic or viral (often following an upper respiratory infection). Other important causes include autoimmune diseases (lupus, rheumatoid arthritis), post-myocardial infarction (Dressler syndrome), uremia (kidney failure), tuberculosis (especially in endemic regions), malignancy, and post-cardiac surgery (post-pericardiotomy syndrome). First-line treatment for acute pericarditis includes NSAIDs (ibuprofen or aspirin) plus colchicine. Colchicine has been shown to significantly reduce recurrence rates. Corticosteroids are reserved for NSAID-contraindicated patients because they paradoxically increase recurrence risk. Pericardial effusion can range from trivial to massive. Small effusions (less than 10 mm on echo) are usually observed. The key concern is whether the effusion causes hemodynamic compromise (tamponade). The classic clinical triad of tamponade is Beck triad: hypotension, distended neck veins (JVD), and muffled heart sounds. Echocardiographic signs include right atrial collapse in systole, right ventricular diastolic collapse, and respiratory variation in mitral and tricuspid inflow velocities (greater than 25% and 40% respectively). Pulsus paradoxus, defined as a drop in systolic blood pressure of more than 10 mmHg during inspiration, is a hallmark physical finding. Constrictive pericarditis occurs when chronic inflammation causes the pericardium to become fibrotic, thickened, and sometimes calcified. This creates a rigid shell that impairs diastolic filling. Clinical features include signs of right heart failure (JVD, ascites, edema) with a characteristic Kussmaul sign (paradoxical rise in JVP during inspiration). The pericardial knock, an early diastolic sound, is specific for constriction.',
      keyTerms: [
        { term: 'Pericardial friction rub', definition: 'A scratchy, high-pitched sound heard on auscultation caused by inflamed pericardial surfaces rubbing against each other' },
        { term: 'Beck triad', definition: 'The classic clinical triad of cardiac tamponade: hypotension, jugular venous distention, and muffled heart sounds' },
        { term: 'Pulsus paradoxus', definition: 'An exaggerated drop (more than 10 mmHg) in systolic blood pressure during inspiration, a key sign of cardiac tamponade' },
        { term: 'Kussmaul sign', definition: 'A paradoxical rise in jugular venous pressure during inspiration, characteristic of constrictive pericarditis' },
        { term: 'Dressler syndrome', definition: 'An autoimmune pericarditis occurring weeks after myocardial infarction or cardiac surgery' },
        { term: 'Colchicine', definition: 'An anti-inflammatory medication that reduces pericarditis recurrence when combined with NSAIDs as first-line therapy' }
      ],
      clinicalNotes: 'When evaluating a patient with pericardial effusion, always assess for tamponade physiology. A large effusion does not necessarily cause tamponade (if chronic), and a small rapidly accumulating effusion can cause tamponade. Clinical status and echocardiographic signs of hemodynamic compromise matter more than effusion size alone.'
    },
    3: {
      level: 3,
      summary: 'Comprehensive pericardial disease management requires understanding the pathophysiology of pericardial inflammation, the hemodynamics of tamponade and constriction, the differentiation of constriction from restriction, and evidence-based pharmacotherapy including colchicine-based regimens.',
      explanation: 'The pathophysiology of acute pericarditis involves activation of the innate immune system. Viral or idiopathic pericarditis triggers an inflammatory cascade with recruitment of neutrophils, macrophages, and lymphocytes to the pericardial tissue. The inflammasome pathway, particularly NLRP3, plays a central role, leading to IL-1beta and IL-18 release. This understanding has driven the investigation of targeted anti-inflammatory therapies including IL-1 receptor antagonists. Recurrent pericarditis affects 15-30% of patients after a first episode and is the most challenging clinical scenario. The COPE, ICAP, and CORP trials established colchicine as a cornerstone of treatment. The CORP-2 trial confirmed that colchicine (0.5 mg twice daily for 3 months for the first episode, 6 months for recurrences) reduces recurrence by approximately 50%. For colchicine-resistant recurrent pericarditis, the AIRTRIP trial demonstrated that anakinra (an IL-1 receptor antagonist) at 2 mg/kg/day (max 100 mg) is highly effective, with recurrence rates dropping from 90% to 18%. The hemodynamics of cardiac tamponade involve equalization of diastolic pressures across all four chambers. As pericardial pressure rises, it compresses the cardiac chambers, first affecting the lowest-pressure chambers (right atrium, then right ventricle). On right heart catheterization, tamponade shows elevated and equalized right atrial pressure, RV diastolic pressure, pulmonary artery diastolic pressure, and pulmonary capillary wedge pressure. The right atrial waveform shows a prominent x-descent with loss of the y-descent (since early diastolic filling is impaired). Constrictive pericarditis physiology is distinct: the rigid pericardium creates ventricular interdependence, meaning that filling of one ventricle directly impairs filling of the other. Catheterization shows the classic "square root sign" or "dip and plateau" pattern in ventricular pressure tracings, and discordant changes in RV and LV systolic pressures with respiration. The differentiation between constrictive pericarditis and restrictive cardiomyopathy is one of the most important clinical challenges. Key distinguishing features include: constriction shows enhanced ventricular interaction (discordant ventricular pressure changes), annulus reversus on tissue Doppler (e' medial > e' lateral, the reverse of normal), and preserved or elevated e' velocities despite impaired filling. CT showing pericardial thickening (greater than 4 mm) or calcification supports constriction. Cardiac MRI with late gadolinium enhancement of the pericardium suggests active pericardial inflammation (potentially transient, constrictive pericarditis) that may respond to anti-inflammatory therapy rather than surgery. Effusive-constrictive pericarditis is a variant where both effusion and constriction coexist; after pericardiocentesis, elevated filling pressures persist due to the constrictive component.',
      keyTerms: [
        { term: 'Annulus reversus', definition: 'Tissue Doppler finding where medial e\' velocity exceeds lateral e\', the reverse of normal, characteristic of constrictive pericarditis' },
        { term: 'Square root sign', definition: 'A hemodynamic pattern on ventricular pressure tracing showing rapid early diastolic dip followed by a plateau, seen in constrictive pericarditis' },
        { term: 'Ventricular interdependence', definition: 'A hemodynamic feature of constriction where filling of one ventricle directly impairs filling of the other within a rigid pericardial space' },
        { term: 'Anakinra', definition: 'An IL-1 receptor antagonist used for colchicine-resistant recurrent pericarditis, shown effective in the AIRTRIP trial' },
        { term: 'Effusive-constrictive pericarditis', definition: 'A variant where pericardial effusion coexists with constrictive physiology, with elevated pressures persisting after drainage' },
        { term: 'Transient constrictive pericarditis', definition: 'A form of constriction that resolves with anti-inflammatory therapy, typically showing pericardial enhancement on MRI indicating active inflammation' }
      ],
      clinicalNotes: 'The constriction vs. restriction distinction has critical therapeutic implications: constriction is surgically curable with pericardiectomy, while restriction due to infiltrative cardiomyopathy (e.g., amyloidosis) is not. Key differentiating tests: (1) Tissue Doppler e\' is preserved or elevated in constriction but reduced in restriction; (2) BNP is typically normal or mildly elevated in constriction but significantly elevated in restriction; (3) Respiratory variation in mitral inflow is enhanced in constriction (>25%) but absent in restriction.'
    },
    4: {
      level: 4,
      summary: 'Advanced pericardial disease management encompasses catheter-based hemodynamic confirmation, multimodality imaging for constrictive physiology, targeted biologics for refractory pericarditis, surgical pericardiectomy techniques, and management of specific etiologies including malignant and tuberculous pericardial disease.',
      explanation: 'Advanced hemodynamic assessment of constrictive pericarditis requires simultaneous right and left heart catheterization with analysis of respiratory variation. The hallmark findings include: (1) Equalization of diastolic pressures (within 5 mmHg) across all chambers; (2) Elevated right atrial pressure with prominent x and y descents (M or W configuration); (3) Square root sign (dip-and-plateau) in ventricular pressure tracings; (4) Discordant RV and LV systolic pressure changes with respiration (when LV pressure increases during expiration, RV pressure decreases, and vice versa); (5) Systolic area index (ratio of RV to LV systolic pressure-time area during inspiration vs. expiration) greater than 1.1 confirms ventricular interdependence. Rapid volume loading during catheterization can unmask occult constriction when baseline hemodynamics are equivocal. Advanced CMR for pericardial disease uses a comprehensive protocol: cine SSFP for ventricular function and septal bounce, real-time free-breathing cine for respiratory ventricular interdependence, T2-weighted sequences for pericardial edema, pre- and post-contrast T1 mapping for pericardial inflammation, and late gadolinium enhancement for active pericardial inflammation vs. fibrosis. Active pericardial enhancement suggests a window for anti-inflammatory therapy before proceeding to pericardiectomy. Pericardiectomy for constrictive pericarditis is performed via median sternotomy. The surgical goal is complete (radical) pericardiectomy from phrenic nerve to phrenic nerve, including the diaphragmatic pericardium. Operative mortality ranges from 6-12%, and is higher in patients with radiation-induced constriction (up to 20%) due to concomitant myocardial fibrosis. Preoperative hepatic function (Model for End-Stage Liver Disease score) and renal function predict perioperative mortality. Importantly, hemodynamic improvement may take weeks to months after surgery as the ventricles gradually adapt to the removal of external constraint. Malignant pericardial disease most commonly results from lung cancer, breast cancer, lymphoma, and melanoma. Large malignant effusions are managed with pericardiocentesis followed by prolonged catheter drainage. Recurrent malignant effusions may require pericardial window creation (subxiphoid or thoracoscopic) or intrapericardial instillation of sclerosing agents or chemotherapeutic agents (cisplatin, thiotepa). Tuberculous pericarditis is common in endemic areas and in HIV-positive patients. Diagnosis may require pericardial fluid analysis showing elevated adenosine deaminase (ADA greater than 40 U/L), positive AFB staining or culture, or pericardial biopsy showing caseating granulomas. Treatment includes standard anti-tuberculosis therapy for 6 months. The role of adjunctive corticosteroids is debated; the IMPI trial showed that prednisolone reduced pericarditis and hospitalization but did not reduce the combined endpoint of death, tamponade, or constriction, and was associated with increased HIV-associated cancers.',
      keyTerms: [
        { term: 'Systolic area index', definition: 'A catheterization-derived ratio quantifying ventricular interdependence, with values greater than 1.1 supporting constrictive pericarditis' },
        { term: 'Radical pericardiectomy', definition: 'Complete surgical removal of the pericardium from phrenic nerve to phrenic nerve, the definitive treatment for constrictive pericarditis' },
        { term: 'Pericardial window', definition: 'A surgical procedure creating an opening in the pericardium to allow continuous drainage of recurrent effusions into the pleural or peritoneal space' },
        { term: 'Adenosine deaminase', definition: 'An enzyme elevated in tuberculous pericardial fluid (>40 U/L), used as a diagnostic marker for tuberculous pericarditis' },
        { term: 'Septal bounce', definition: 'An abnormal rapid early diastolic motion of the interventricular septum seen on echocardiography or CMR, reflecting ventricular interdependence in constriction' }
      ],
      clinicalNotes: 'Before proceeding to pericardiectomy, trial of aggressive anti-inflammatory therapy (3-6 months) is warranted if CMR shows active pericardial inflammation (LGE of pericardium), as this may represent transient constrictive pericarditis. Up to 15-20% of patients with apparent constriction will normalize with medical therapy alone. Risk stratification before pericardiectomy should include assessment of hepatic congestion (elevated bilirubin, INR), renal function, and radiation exposure history, as these predict higher surgical mortality.'
    },
    5: {
      level: 5,
      summary: 'Expert-level pericardial disease management integrates precision immunomodulatory therapy, advanced hemodynamic assessment including exercise hemodynamics for occult constriction, emerging biologic agents, genetic susceptibility in recurrent pericarditis, and complex decision-making for radiation-induced and post-surgical pericardial syndromes.',
      explanation: 'The molecular pathogenesis of idiopathic recurrent pericarditis involves autoinflammatory mechanisms. Whole-exome sequencing studies have identified variants in innate immune genes including TNFRSF1A (TNF receptor superfamily), MEFV (Mediterranean fever gene), and NLRP3 (inflammasome) in a subset of patients with recurrent pericarditis, suggesting overlap with periodic fever syndromes. This has led to the concept of "autoinflammatory pericarditis" as distinct from classic autoimmune pericarditis. The pivotal phase III RHAPSODY trial of rilonacept (an IL-1 alpha/beta trap) demonstrated rapid resolution of pericarditis pain and CRP, with significant reduction in recurrence (7% vs. 74% placebo), leading to FDA approval as the first targeted therapy for recurrent pericarditis. Rilonacept (320 mg loading dose, then 160 mg weekly subcutaneously) enables tapering of corticosteroids and colchicine. Other IL-1 inhibitors under study include canakinumab (anti-IL-1beta monoclonal antibody) and goflikicept. Intravenous immunoglobulin (IVIG) has shown efficacy in case series for refractory recurrent pericarditis, potentially by modulating autoantibody-mediated inflammation. Occult constrictive pericarditis presents a diagnostic challenge: patients have symptoms of heart failure with normal resting hemodynamics. Exercise hemodynamic assessment (performed during catheterization or with Doppler echocardiography during exercise) unmasks elevated filling pressures and ventricular interdependence during exertion. Invasive exercise testing showing a wedge pressure exceeding 25 mmHg with exercise, combined with discordant ventricular pressure changes, confirms the diagnosis. This subset benefits from pericardiectomy with outcomes comparable to overt constriction. Radiation-induced pericardial disease deserves special consideration. Mediastinal radiation (for Hodgkin lymphoma, breast cancer, etc.) causes progressive pericardial fibrosis that may manifest as constriction decades after exposure. However, radiation also causes concomitant myocardial fibrosis, coronary artery disease, and valvular disease. The coexistence of restrictive physiology from myocardial fibrosis with constrictive physiology from pericardial fibrosis (so-called "mixed constrictive-restrictive" physiology) complicates diagnosis and worsens surgical outcomes. Pericardiectomy in radiation-induced constriction carries mortality of 15-20%, and long-term outcomes are worse because removing the pericardium does not address the underlying myocardial disease. Careful assessment of myocardial reserve (e.g., contractile reserve on dobutamine stress echo, myocardial fibrosis on CMR) is essential before recommending surgery. Post-cardiac surgery pericardial syndromes include postpericardiotomy syndrome (PPS, occurring in 10-40% of cardiac surgeries), which is an immune-mediated inflammatory response to surgical pericardial injury. Anti-heart antibodies and elevated anti-heart reactive protein levels are found. Colchicine prophylaxis (COPPS trial) reduces PPS incidence by approximately 50% when initiated on postoperative day 3. The COPPS-2 trial confirmed this in a larger cohort. For complex recurrent PPS, the same IL-1 inhibitor escalation pathway used in idiopathic recurrent pericarditis applies. The emerging concept of pericardial access for electrophysiology procedures (epicardial ablation for ventricular tachycardia) has introduced a new category of iatrogenic pericardial disease. The anterior approach (Sosa technique) and the inferior approach carry risks of pericardial effusion, tamponade, and subsequent pericarditis. Understanding pericardial anatomy and adhesion patterns in post-surgical patients is critical for planning epicardial access.',
      keyTerms: [
        { term: 'Rilonacept', definition: 'An IL-1 alpha/beta cytokine trap approved by the FDA for recurrent pericarditis, shown effective in the RHAPSODY trial' },
        { term: 'Autoinflammatory pericarditis', definition: 'A subset of recurrent pericarditis driven by innate immune dysregulation with variants in inflammasome or periodic fever syndrome genes' },
        { term: 'RHAPSODY trial', definition: 'The pivotal phase III trial demonstrating rilonacept efficacy in reducing recurrence of pericarditis and enabling corticosteroid tapering' },
        { term: 'Occult constrictive pericarditis', definition: 'Constrictive physiology that is only unmasked during exercise hemodynamic assessment, with normal resting hemodynamics' },
        { term: 'Postpericardiotomy syndrome', definition: 'An immune-mediated inflammatory pericarditis occurring after cardiac surgery, reducible with prophylactic colchicine' },
        { term: 'Mixed constrictive-restrictive physiology', definition: 'Coexisting pericardial constriction and myocardial restriction, typically from radiation damage, complicating diagnosis and worsening surgical outcomes' }
      ],
      clinicalNotes: 'The treatment escalation algorithm for recurrent pericarditis in 2024+ is: (1) NSAID + colchicine as first-line; (2) Low-dose corticosteroid added for NSAID failure/intolerance; (3) Rilonacept or anakinra for corticosteroid-dependent or colchicine-resistant disease; (4) IVIG, azathioprine, or mycophenolate as alternatives; (5) Pericardiectomy as last resort for refractory cases. Key principle: very slow corticosteroid taper (decrease by no more than 2.5 mg prednisone every 2-4 weeks) under colchicine cover, as rapid tapering is the most common cause of recurrence.'
    }
  },
  media: [],
  citations: [
    {
      id: 'adler-2015',
      text: 'Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. 2015;36(42):2921-2964.',
      url: 'https://doi.org/10.1093/eurheartj/ehv318'
    },
    {
      id: 'imazio-2013',
      text: 'Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP-2): a randomized trial. Ann Intern Med. 2013;159(12):1-7.',
      url: 'https://doi.org/10.7326/0003-4819-159-12-201312170-00002'
    },
    {
      id: 'klein-2020',
      text: 'Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease. J Am Soc Echocardiogr. 2013;26(9):965-1012.',
      url: 'https://doi.org/10.1016/j.echo.2013.06.023'
    }
  ],
  crossReferences: [
    { contentId: 'myocarditis', relationship: 'related', description: 'Myopericarditis involves overlapping inflammation of the myocardium and pericardium' },
    { contentId: 'heartfailure', relationship: 'related', description: 'Constrictive pericarditis is an important treatable cause of right heart failure' }
  ],
  tags: {
    defined: ['pericarditis', 'pericardial-effusion', 'cardiac-tamponade', 'constrictive-pericarditis', 'pericardiocentesis', 'colchicine', 'rilonacept', 'beck-triad'],
    source: ['ESC', 'AHA', 'ACC']
  },
  createdAt: '2025-01-25',
  updatedAt: '2025-01-25',
  version: 2,
  status: 'published'
};
